Eris Lifesciences (ERIS) investor relations material

Executive summary

• Consolidated revenue for FY26 grew 8% year-over-year to INR 3,129 crore, with EBITDA up 10% and margin expanding to 37%.

• Domestic Branded Formulations (DBF) segment delivered 11% revenue growth and 12% EBITDA growth for FY26, maintaining a 37% margin.

• International business revenue increased 7% year-over-year, impacted by supply chain disruptions and regulatory delays.

• Audited standalone and consolidated financial results for FY26 were approved, with unmodified audit opinions issued.

• Interim dividend of ₹7.21 per share declared for FY 2026-27, with record date set for May 29, 2026.

Financial highlights

• Q4 consolidated revenue: INR 757 crore; full year: INR 3,129 crore.

• Q4 consolidated PAT: INR 132 crore (29% growth); full year: INR 498 crore (34% growth); reported PAT was INR 648 crore due to a one-off deferred tax gain.

• Standalone revenue for FY26 was INR 1,821.74 crore; standalone net profit was INR 244.05 crore.

• Exceptional item of INR 17.24 crore (consolidated) due to increased gratuity and leave liability from new labour codes.

• Finance cost for FY26 declined 17% year-over-year; net debt reduced to 2x EBITDA.

Outlook and guidance

• DBF FY27 revenue expected to grow 30% above covered market growth, with EBITDA margin guidance at 37%.

• International business FY27 revenue guidance is 18%-20% growth, excluding EU CDMO upside.

• H2 FY27 margins expected to be higher than H1 for DBF.

• Eligible to opt for concessional tax regime from FY 2026-27, with deferred tax assets and liabilities remeasured.

• EU CDMO revenue of INR 120-140 crore postponed pending facility re-approval.